Therefore, we speculate that the function of FoxO may be dependent on the activation level and tissue location, of course, which requires further basic and animal experiments, and even future clinical experiments to discover the mechanism of the contradictory functions, revealing whether the activation of FoxO3 would bring other side effects when promoting OS in BMSCs, such as skeletal muscle atrophy. This evidence concerns the gene FOXO3 and muscular atrophy.